Can pretreatment serum @entity460 level predict the efficacy of @entity1499 in the treatment of severe XXXX ?

@entity1 @entity1569 @entity6822 @entity19 @entity460 @entity1499
BACKGROUND: The efficacy of @entity1499 ( @entity6822 ) varies in the treatment of @entity1569 . OBJECTIVE: We sought to identify an indicator from routine pretreatment tests to predict @entity6822 efficacy in the treatment of @entity1569 . METHODS: In a retrospective analysis of 77 psoriatic @entity1 , the correlation between @entity6822 efficacy and pretreatment routine test results was analyzed with Spearman correlation. The potential risks were further evaluated with a linear regression model. Receiver operating characteristic analysis was performed to examine the effectiveness of serum total @entity460 (tCa) to predict the effect of @entity6822 on @entity1569 . The highest Youden index was used to determine the cutoff point, with which the positive and negative predictive values were calculated. Synergistic effects of @entity6822 and @entity460 on keratinocyte growth and @entity1569 -like @entity19 model were also investigated. RESULTS: The pretreatment tCa level exhibited the closest association with @entity6822 efficacy. The relative @entity1569 improvement with tCa was 61.07% (95% confidence interval, 42.85-79.29; P  <  .001) and better improvements were observed in @entity1 with higher tCa (r  =  0.588; P  <  .002). @entity6822 inhibited keratinocyte growth, which was enhanced synergistically by @entity460 . In a @entity1569 -like @entity19 model, @entity6822 strongly inhibited epidermis proliferation in the high- @entity460 group. LIMITATIONS: One limitation of our study is the relatively small sample size. CONCLUSION: Pretreatment tCa level has the highest correlation with @entity6822 efficacy, which might be useful  in  predicting beneficial treatment results in @entity1569 . Larger studies are required to confirm our findings.
